Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial
Universitair Ziekenhuis Leuven · KU Leuven · +32 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
963
total citations
- FWCI
- 46.07
- Percentile
- 100%
- References
- 30
Citations per year
Authors
28- JMJohan Maertens
Universitair Ziekenhuis Leuven, KU Leuven
- IRIssam Raad
The University of Texas MD Anderson Cancer Center
- KAKieren A. Marr
Johns Hopkins University
- TFThomas F. Patterson
The University of Texas Health Science Center, South Texas Veterans Health Care System, The University of Texas Health Science Center at San Antonio
- DPDimitrios P. Kontoyiannis
The University of Texas MD Anderson Cancer Center
Topics & keywords
Topics
Keywords
- Voriconazole
- Medicine
- Clinical endpoint
- Internal medicine
- Population
- Adverse effect
- Clinical trial
- Surgery
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.